Bortezomib in Treating Patients With Chronic Myelogenous Leukemia

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of bortezomib in treating patients who have chronic myelogenous leukemia in chronic or accelerated phase.

Timeline

Start

2001-07-02

Primary completion

2005-03

Completion

2005-03

Outcome

Outcome not reported

Stopped: “Lack of efficacy”

Drugs

Indications